Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Jun Sung Lee 1 Article
Mechanism of Anti-α-Synuclein Immunotherapy
Jun Sung Lee, Seung-Jae Lee
J Mov Disord. 2016;9(1):14-19.   Published online January 25, 2016
DOI: https://doi.org/10.14802/jmd.15059
  • 23,461 View
  • 307 Download
  • 33 Citations
AbstractAbstract PDF
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.

Citations

Citations to this article as recorded by  
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
    Shin Hye Noh, Ye Jin Kim, Min Goo Lee
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
    Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
    Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
    Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593.     CrossRef
  • Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
    Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
    Immunology.2021; 162(2): 160.     CrossRef
  • Electrogastrography for diagnosis of early-stage Parkinson's disease
    Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
    Parkinsonism & Related Disorders.2021; 86: 61.     CrossRef
  • Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
    Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
    Molecules.2021; 26(12): 3736.     CrossRef
  • Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
    Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
    Neurochemical Research.2021; 46(12): 3123.     CrossRef
  • Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
    Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
    CNS & Neurological Disorders - Drug Targets .2021; 20(9): 802.     CrossRef
  • Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
    Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
    Pharmacological Reviews.2021; 73(4): 1204.     CrossRef
  • Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
    Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
    Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
    Translational Neurodegeneration.2020;[Epub]     CrossRef
  • Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
    James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
    Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
    Molecular Neurobiology.2019; 56(7): 4799.     CrossRef
  • The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
    Datis Kharrazian, Martha Herbert, Aristo Vojdani
    Toxics.2019; 7(2): 26.     CrossRef
  • Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model
    Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
    Alzheimer's & Dementia.2019; 15(9): 1133.     CrossRef
  • Translational therapies for multiple system atrophy: Bottlenecks and future directions
    Nadia Stefanova
    Autonomic Neuroscience.2018; 211: 7.     CrossRef
  • Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
    Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
    Redox Biology.2018; 14: 600.     CrossRef
  • Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
    Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
    Journal of Neuroimmunology.2018; 315: 33.     CrossRef
  • Beneficial Effects of Flavonoids Against Parkinson's Disease
    Un Ju Jung, Sang Ryong Kim
    Journal of Medicinal Food.2018; 21(5): 421.     CrossRef
  • Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
    Jiyoon Kim, Heon Yung Gee, Min Goo Lee
    Journal of Cell Science.2018;[Epub]     CrossRef
  • Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
    Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
    Frontiers in Neuroscience.2018;[Epub]     CrossRef
  • Gene therapy for neurological disorders: progress and prospects
    Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
    Nature Reviews Drug Discovery.2018; 17(9): 641.     CrossRef
  • Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
    Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
    Journal of Neural Transmission.2017; 124(6): 721.     CrossRef
  • Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
    Xiaoli Si, Jiali Pu, Baorong Zhang
    Journal of Movement Disorders.2017; 10(2): 69.     CrossRef
  • Membrane Trafficking Illuminates a Path to Parkinson’s Disease
    Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
    The Tohoku Journal of Experimental Medicine.2017; 242(1): 63.     CrossRef
  • Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
    J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
    Scientific Reports.2017;[Epub]     CrossRef
  • Impact of aging immune system on neurodegeneration and potential immunotherapies
    Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
    Progress in Neurobiology.2017; 157: 2.     CrossRef
  • A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
    Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
    PLOS ONE.2017; 12(9): e0184731.     CrossRef
  • Vaccination strategies in tauopathies and synucleinopathies
    Anne K. Braczynski, Jörg B. Schulz, Jan-Philipp Bach
    Journal of Neurochemistry.2017; 143(5): 467.     CrossRef
  • Missions of <italic>Journal of Movement Disorders</italic>
    Yun Joong Kim
    Journal of Movement Disorders.2016; 9(1): 1.     CrossRef
  • How strong is the evidence that Parkinson's disease is a prion disorder?
    Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
    Current Opinion in Neurology.2016; 29(4): 459.     CrossRef

JMD : Journal of Movement Disorders